400results about "Peptide-nucleic acids" patented technology

Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.

The invention relates to coacervate-forming polymers having defined structural formulae. The invention also relates solutions comprising the coacervate-forming polymers and methods of making solutions comprising the coacervate-forming polymers. The invention also relates to polymer coacervates, comprising the coacervate-forming polymers within the coacervates, including polymer coacervates comprising cargo compounds, and methods for making such polymer coacervates. The coacervates of the invention are capable of penetrating into cells and thereby delivering cargo compounds into cells. The invention further relates to compositions, including pharmaceutical compositions, comprising the polymer coacervates. The invention also relates to uses of the coacervate-forming polymers, including medical uses.

Disclosed herein are compositions for use in controlling fungal diseases, wherein the compositions comprise novel alpha-factor-derived anti-fungal peptides, or one or more polynucleotides encoding for the one or more antifungal peptides.

The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and / or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.

The present invention provides an hBCMA-binding polypeptide comprising at least one motif that binds to hBCMA, wherein the peptide has the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the hBCMA-binding motif is the portion [Helix 1]-[Spacer portion]-[Helix 2]. The present invention further provides a pharmaceutical composition comprising the hBCMA-binding polypeptide, and the use of the hBCMA-binding polypeptide or the pharmaceutical composition for use as a medicament, particularly for the treatment or prevention of cancer.

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.

Disclosed herein are to peptide bundlemers that possess one or more hydrophobic groups on the surface that are capable of assembling into lattice nanostructures, amorphous networks and liquid crystalline structures in solution. Methods of creating these structures and articles formed from these structures are also disclosed.

The present disclosure provides a method for treating cancer, which includes, inter alia, a) an intratumoral cell lysis step mediated by cryolysis, and b) an intratumoral administration step of a combination of immunotherapeutic agents including: 1) i) a TLR9 agonist CpG oligodeoxynucleotide, ii) an agonistic anti-CD40 monoclonal antibody, iii) an agonistic anti-OX40 monoclonal antibody, and iv) an anti-CTLA4 monoclonal antibody, or 2) i) a TLR9 agonist CpG oligodeoxynucleotide, ii) an agonistic anti-CD40 monoclonal antibody, iii) an anti-PD1 monoclonal antibody, and iv) an anti-CTLA4 monoclonal antibody.

Use of the peptide identified as SEQ ID NO: 1 for manufacturing a medicine which induces antitumor and antiviral immunity by immunogenic cell death. The invention also provides a method for treating cancer or viral infections by using therapeutically effective amounts of a drug that comprises the synthetic peptide of the invention. This method induces antitumor and antiviral immunity by immunogenic cell death. Also, the invention comprises the pharmaceutical combination of the peptide identified as SEQ ID NO: 1 and cancer immunotherapy approaches, which achieve stronger immunotherapeutic management to combat this disease.

Provided are: a peptide having insecticidal activity and containing an amino acid sequence represented by SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 7, or an amino acid sequence containing one to several amino acid mutations in SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 7; an insecticidal composition containing the peptide; and a pest control method using the peptide.

The present invention relates to novel peptides, compositions and kits comprising said peptides, for use as active ingredients for preventing or treating pain in a subject in need thereof. In vitro or ex vivo methods for modulating the expression of these peptides are also described herein.

A peptide which is characterized by: (a) dissolving 2 g or more at 20 DEG C in 100 mL of a 50 mM Tris hydrochloric acid buffer solution (pH 7.5) containing 0.3 M sodium chloride; (b) reversibly performing phase change in the Tris hydrochloric acid buffer solution, wherein the transformation temperature is 40-70 DEG C when 2g of the solution is dissolved in 100mL of the Tris hydrochloric acid buffer solution; and (c) when 2 g of the Tris hydrochloric acid buffer solution is dissolved in 100 mL of the Tris hydrochloric acid buffer solution, droplets are formed under the temperature condition above the transition temperature.

Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and / or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Problem The purpose of the present invention is to provide a novel method for prevention and / or treatment of opioid tolerance or opioid dependence. Specifically, the purpose of the present invention is to develop peptide-based blockers to block MOR-DOR and KOR-DOR heterodimerization. In addition, the purpose of the present invention is to develop homodimer blockers for MOR, DOR, and KOR which modulate their downstream signaling without affecting their internalization. Solution The present invention is a prophylactic and / or therapeutic agent for the prevention and / or treatment of opioid tolerance or opioid dependence comprising the peptide which inhibits the dimer formation of the opioid receptor, wherein the above opioid receptor dimer is a heterodimer or a homodimer formed from one or two opioid receptors selected from the group consisting of the μ type (MOR), the κ type (KOR), and the δ type (DOR).

The invention relates to a compound of formula (I), which is a synthetic collagen related peptide, in the form of a double cross-linked trimer. The invention extends to a composition comprising a compound of formula (II) and formula (III), where formula (II) is a synthetic collagen related peptide, in the form of a double cross-linked trimer, and formula (III) is a synthetic collagen related peptide, in the form of a double cross-linked dimer. The invention also extends to a method of producing the compound of formula (II). The invention also extends to medical uses of the compound and the composition, including treating a skin condition, and methods of cosmetic treatment using the compound and the composition.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The present invention provides synthetic peptides, compositions containing synthetic peptides, and methods for modifying the complement system. [Solution] The present invention relates to the modification of a 15-amino acid synthetic peptide from polar assortant (PA) peptides, which are scrambled peptides derived from human astrovirus protein. In some embodiments, the present invention relates to peptides that are modified PAs, which are stapled and / or have D-enantiomer substitutions of certain amino acids, and which include sarcosine substitutions at certain amino acid positions. The present invention further provides a method for selecting at least one synthetic peptide to treat various conditions.

The invention discloses a self-assembled nano-capture antibacterial peptide KIL4 and a preparation method and application thereof, and belongs to the technical field of biology, and the amino acid sequence is shown as SEQ ID No.1. The preparation method comprises the following steps: adopting an alpha-spiral heptapeptide repetitive sequence (abcdefg) 4 template, and selecting lysine to provide positive charges at positions b and c; isoleucine and leucine are respectively filled to a position a and a position d to provide intermolecular hydrophobic force, and lysine and glutamic acid are selected to be respectively filled to a position e and a position g to provide intermolecular electrostatic force; the position f of the center of the hydrophilic surface of the polypeptide is filled with tryptophan to optimize the hydrophobicity of the polypeptide, on the basis, the sequence is repeated for four times, and the invention further discloses application of the polypeptide in preparation of drugs for treating gram-positive bacteria or / and gram-negative bacteria infectious diseases. The antibacterial peptide disclosed by the invention has dual effects of resisting bacteria and capturing bacteria, has excellent biocompatibility, and provides an effective technical support for developing novel antibacterial drugs.

Disclosed in the present invention are an immunoglobulin x-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the V4-1-IgLC polypeptide is as shown in SEQ ID NO. 1, and the polypeptide can be used as a target or a marker for preparing a drug for diagnosing and / or treating tumors or inflammatory diseases, and can also be used for preparing an Integrin-FAK signal pathway inhibitor. An antibody prepared by using the polypeptide as an antigen can effectively inhibit the development of tumors, and provides a new thought for clinical diagnosis and treatment of tumors.

Disclosed are color care compositions and color care, fragrance booster compositions in particulate form comprising an artificial peptide capable of scavenging chlorine. The artificial peptide can further have textile binding capabilities to provide carryover benefits from a wash cycle to a rinse cycle.

The invention relates to peptide-based non-protein load delivery. Methods, compositions, kits and synthetic peptide shuttle agents related to transduction of protein and / or non-protein loads are described. The methods generally include contacting a target eukaryotic cell with a non-protein load and a synthetic peptide shuttle at a concentration sufficient to increase the transduction efficiency of the non-protein load compared to the absence of the synthetic peptide shuttle. The non-protein load may be a drug for the treatment of disease, such as a small molecule drug. The invention also describes novel synthetic peptide shuttles having transduction activity on protein and / or non-protein loads, as well as the use of propidium iodide or other membrane impermeable fluorescent DNA intercalators as alternative loads for selecting multifunctional synthetic peptide shuttles having transduction activity on both protein and non-protein loads.

The present invention provides synthetic peptides. The present invention relates to modified 15-amino acid synthetic peptides from the Polar Assortant (PA) peptide, a scrambled peptide derived from a human astrovirus protein. In some embodiments, the present invention relates to peptides that are modified versions of PA, including sarcosine substitutions at certain amino acid positions, that are stapled, and / or have D-enantiomeric substitutions of certain amino acids. The present invention further provides methods for selecting at least one synthetic peptide for treating various conditions. TIFF2023548344000031.tif38142

To provide a recombinant acid-resistant yeast with lactic acid-producing ability and suppressed glycerol production and a method of producing lactic acid using the same.SOLUTION: There is provided a recombinant strain having lactic acid-producing ability, in which a gene encoding an enzyme that converts dihydroxyacetone phosphate to glycerol-3-phosphate is deleted or attenuated from an acid-resistant yeast YBC strain (KCTC13508BP) and in which a gene encoding lactate dehydrogenase is introduced into the acid-resistant yeast YBC strain. Also provided is a method of preparing lactic acid using the recombinant strain.SELECTED DRAWING: Figure 2

The present invention relates to a peptide having a lipolytic effect, and more particularly, to a composition for preventing, ameliorating or treating obesity comprising the peptide. The peptide having a lipolytic efficacy according to the present invention has excellent effects of reducing intracellular lipid droplets, reducing orange peel tissue, improving skin roughness, and reducing the interface length between dermis and subcutaneous fat layer, and can be used variously in the field of prevention, improvement, or treatment of obesity.

Described herein are improved cell penetrating peptides and related compositions and methods.

The application belongs to the technical field of genetic engineering, and particularly relates to an antibacterial peptide with antibacterial and antiviral effects, application and product thereof. The amino acid sequence of the antibacterial peptide has the following general formula: X1GX2FX3FX4KKFX5LFX6X7SKVLK; X1 is M or no amino acid; X2 is one of R, G and H; X3 is one of KS, KR, HR and HH; X4 is R or L; X5 is one of KK, HH and HK; X6 is RR or KK; and X7 is I or L. The antibacterial peptide has good antibacterial effect, and shows antiviral activity to HPV16 and HPV18. The antibacterial peptide shows good application prospect in preparation of antibacterial or antiviral products.

Peptides and Peptide-lipid conjugates are provided in which the peptide has the general Formula (I), wherein, A1 is selected from serine, threonine, O-C1-6 alkyl serine, and O-C1-6 alkyl threonine; A2 is selected from serine, threonine, O-C1-6 alkyl serine, and O-C1-6 alkyl threonine; A3 is selected from glutamic acid, glutamine, asparagine, and aspartic acid; A4 is proline; each A5 is independently selected from a natural or modified amino acid; The peptide-lipid conjugates can be used in lipid formulations for the delivery of nucleic acids.